Gleevec, a pill developed in conjunction with Oregon Health & Science University is again showing excellent results in preventing cancer recurrence in GIST patients after complete removal of their tumors.
A generic drug already used by millions of Americans for high blood pressure and prostate problems has been found to improve sleep and lessen trauma nightmares in veterans with posttraumatic stress disorder (PTSD).
Nutrition experts at the Moores UCSD Cancer Center and Scripps Clinic in Del Mar are seeking obese men and women to participate in a research study for weight loss employing an investigational combination drug therapy and behavioral modification.
An influenza vaccine produced with the use of insect cells appeared safe and produced an immunogenic response in healthy adults, suggesting promise as an alternative to using embryonated eggs for the development of influenza vaccine, according to a preliminary study in the April 11 issue of JAMA.
Patients who receive corticosteroids after cardiac surgery have a significantly lower risk of atrial fibrillation in the days following the surgery, according to a study in the April 11 issue of JAMA.
An experimental flu vaccine made in insect cells ? not in eggs, where flu vaccines currently available in the United States are grown ? is safe and as effective as conventional vaccines in protecting people against the flu, according to results published in the April 11 issue of the Journal of the American Medical Association.
A drug for epilepsy with a new mechanism of action is safe and effective, according to a study published in the April 10, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.
A new clinical trial examines the effectiveness of a new vaccine designed to control the spread of cancer cells in people with Stage four kidney cancer.
The Gerald P. Murphy Cancer Foundation announced the launch of the first randomized, double blind, placebo-controlled cancer prevention trial in pet dogs.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), provides comment on a re-analysis of pooled data from both hormone therapy arms of the Women?s Health Initiative (WHI) Study published in the Journal of the American Medical Association.